Impaired IFN-α production and the risk of cancer development

Journal of Interferon and Cytokine Research

Volumn 27, Issue 12, 2007, Pages 1013-1017

  Uno, Kazuko ^a   Hirosaki, Mayumi ^b   Kakimi, Kazuhiro ^c   Tominaga, Masumi ^d   Suginoshita, Yoshiki ^e   Hasegawa, Goji ^d   Fukui, Michiaki ^d   Nakamura, Naoto ^d   Shirakawa, Taro ^b   Kishida, Tsunataro ^a  

^a Louis Pasteur Center for Medical Research   (Japan)

^b KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; SENDAI VIRUS;

HEPATITIS C VIRUS; SENDAI VIRUS;

EID: 38049025272     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0047     Document Type: Article

References (21)

1. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000;356:1795-1799.
2. Reid LM, Minato N, Gresser I, Holland J, Kadish A, Bloom BR. Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice. Proc. Natl. Acad. Sci. USA 1981;78:1171-1175.
3. Gresser I, Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev. 2002;13:111-118.
4. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 2005;6:722-729.
5. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003;424:516-523.
6. Uno K, Nakano K, Maruo N, Onodera H, Mata H, Kurosu I, Akatani K, Ikegami N, Kishi A, Yasuda Y, Tanaka K, Setoguchi J, Kondo M, Muramatsu S, Kishida T. Determination of interferon-α-producing capacity in whole blood cultures from patients with various diseases and from healthy persons. J. Interferon Cytokine Res. 1996;16:911-918.
7. Uno K, Suginoshita Y, Kakimi K, Moriyasu F, Hirosaki M, Shirakawa T, Kishida T. Impairment of IFN-alpha production capacity in patients with hepatitis C virus and the risk of the development of hepatocellular carcinoma. World J. Gastroenterol. 2005;11:7330-7334.
8. Bennett JM, Kouides PA, Forman SJ. The myelodysplastic syndromes: morphology, risk assessment, and clinical management. Int. J. Hematol. 2002;76 (Suppl 2):228-238.
9. Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK, Ahlquist DA, Melton LJ 3rd, Sellers TA, Cerhan JR. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am. J. Gastroenterol. 2006;101:1872-1879.
10. Wood C, Harrington W Jr. AIDS and associated malignancies. Cell Res. 2005;15:947-952.
11. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996;23:695-699.
12. Seeff LB. Natural history of hepatitis C. Hepatology 1997;26:21S-28S.
13. Tanaka E, Kiyosawa K. Natural history of acute hepatitis C. J. Gastroenterol. Hepatol. 2000;15:E97-104.
14. Akahoshi M, Ishihara M, Remus N, Uno K, Miyake K, Hirota T, Nakashima K, Matsuda A, Kanda M, Enomoto T, Ohno S, Nakashima H, Casanova JL, Hopkin JM, Tamari M, Mao XQ, Shirakawa T. Association between IFNA genotype and the risk of sarcoidosis. Hum. Genet. 2004;114:503-509.
15. Uno K, Shimizu S, Ido M, Naito K, Inaba K, Oku T, Kishida T, Muramatsu S. Direct and indirect effects of interferon on in vivo murine tumor cell growth. Cancer Res. 1985;45:1320-1327.
16. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, Tough DF. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002;99:3263-3271.
17. Anthony DD, Yonkers NL, Post AB, Asaad R, Heinzel FP, Lederman MM, Lehmann PV, Valdez H. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J. Immunol. 2004;172:4907-4916.
18. Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T, Oki C, Itose I, Hiramatsu N, Takehara T, Kasahara A, Hayashi N. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J. Infect. Dis. 2004;190:1919-1926.
19. Kanto T, Inoue M, Miyazaki M, Itose I, Miyatake H, Sakakibara M, Yakushijin T, Kaimori A, Oki C, Hiramatsu N, Kasahara A, Hayashi N. Impaired function of dendritic cells circulating in patients infected with hepatitis C virus who have persistently normal alanine aminotransferase levels. Intervirology 2006;49:58-63.
20. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
21. Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection. Intervirology 2004;47:355-361.